The independent source for health policy research, polling, and news.
Showing 21 - 40 of 88
The pharmaceutical industry has invented a new art form: finding ways to make their wares seem like joyous must-have treatments, while often minimizing lackluster efficacy and risks.
杨贵妃传媒視頻 Health News and The New York Times are looking into a dreaded 鈥渁dulting鈥 milestone: finding your own medical insurance at 26.
Legal maneuvering, industry lobbying, and lax IRS oversight leave lots of room for 鈥渙perating surpluses.鈥
Even when patients double-check that their care is covered by insurance, health providers often send them bills as they haggle with insurers over reimbursement, which can last for months. It鈥檚 stressful and annoying 鈥 but legal.
A popular scale for measuring pain doesn鈥檛 work, but medicine still has no better alternative.
One of the most unfair aspects of medical insurance is this: Patients can change insurance only during end-of-year enrollment periods or at the time of 鈥渜ualifying life events.鈥 But insurers鈥 contracts with doctors, hospitals, and pharmaceutical companies can change abruptly at any time.
Resorting to crowdfunding to pay medical bills has become so routine, in some cases health professionals recommend it.
It鈥檚 a big job clearing out so-called 鈥減atent thickets鈥 drugmakers create to keep their products鈥 prices high. But the Federal Trade Commission is giving it a shot.
The designers of the Affordable Care Act might have assumed that they spelled out with sufficient clarity that millions of Americans would no longer have to pay for certain types of preventive care. But they didn鈥檛 reckon with America鈥檚 ever-creative medical billing juggernaut.
At $1,000 a night for a private room, medical centers are offering fancy food and casting health care as a 鈥渏ourney.鈥 Instead of creature comforts, how about helping us feel better?
The CDC鈥檚 RSV vaccination recommendations beg the question: How much should an immunization that will possibly be given to millions of Americans cost to be truly valuable?
The declining share of U.S. doctors in adult primary care is about 25% 鈥 a point beyond which many Americans won鈥檛 be able to find a family doctor at all.
Brand-name drug prices in the U.S. 鈥 more than three times the price in other developed countries 鈥 are related neither to the amount of research and development required to bring them to market nor their therapeutic value, recent research shows. Have drugmakers overplayed their hand?
After decades of unchecked mergers, health care is the land of giants, with huge medical systems monopolizing care in many cities, states, and even whole regions of the country. This decreases patient choice, impedes innovation, erodes quality of care, and raises prices. And federal regulators have been slow to act.
Stay informed by signing up for the Morning Briefing and other emails:
漏 2026 KFF